LeMaitre Vascular (NASDAQ:LMAT) Raised to Buy at StockNews.com

LeMaitre Vascular (NASDAQ:LMAT) was upgraded by investment analysts at StockNews.com from a “hold” rating to a “buy” rating in a research report issued on Wednesday.

A number of other brokerages also recently weighed in on LMAT. Lake Street Capital initiated coverage on shares of LeMaitre Vascular in a report on Friday, August 2nd. They set a “buy” rating and a $105.00 price target for the company. Cantor Fitzgerald assumed coverage on shares of LeMaitre Vascular in a research note on Tuesday, October 15th. They issued a “neutral” rating and a $96.00 price objective for the company. JMP Securities raised their price target on shares of LeMaitre Vascular from $77.00 to $100.00 and gave the company a “market outperform” rating in a research note on Tuesday, August 20th. Barrington Research raised their price target on shares of LeMaitre Vascular from $92.00 to $93.00 and gave the company an “outperform” rating in a research note on Friday, November 1st. Finally, Oppenheimer reiterated an “outperform” rating and set a $93.00 price objective (up from $90.00) on shares of LeMaitre Vascular in a research report on Friday, November 1st. Two investment analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, LeMaitre Vascular has a consensus rating of “Moderate Buy” and an average target price of $94.57.

LeMaitre Vascular Stock Performance

LMAT traded up $3.08 on Wednesday, reaching $101.71. The company had a trading volume of 237,196 shares, compared to its average volume of 121,780. The company’s fifty day moving average is $90.13 and its 200 day moving average is $83.87. LeMaitre Vascular has a fifty-two week low of $47.72 and a fifty-two week high of $103.96. The stock has a market cap of $2.29 billion, a P/E ratio of 55.58, a P/E/G ratio of 2.36 and a beta of 0.89.

LeMaitre Vascular (NASDAQ:LMAT) last announced its earnings results on Thursday, October 31st. The medical instruments supplier reported $0.49 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.44 by $0.05. LeMaitre Vascular had a net margin of 19.40% and a return on equity of 13.15%. The firm had revenue of $54.82 million for the quarter, compared to analyst estimates of $53.50 million. During the same quarter in the prior year, the business posted $0.33 EPS. The business’s revenue was up 15.6% compared to the same quarter last year. On average, sell-side analysts expect that LeMaitre Vascular will post 1.94 EPS for the current year.

Insider Activity at LeMaitre Vascular

In other LeMaitre Vascular news, Director David B. Roberts sold 3,063 shares of LeMaitre Vascular stock in a transaction dated Tuesday, August 13th. The shares were sold at an average price of $82.07, for a total value of $251,380.41. Following the sale, the director now owns 14,114 shares of the company’s stock, valued at approximately $1,158,335.98. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. 10.79% of the stock is owned by insiders.

Institutional Trading of LeMaitre Vascular

Hedge funds have recently added to or reduced their stakes in the stock. CANADA LIFE ASSURANCE Co increased its stake in shares of LeMaitre Vascular by 44.7% in the first quarter. CANADA LIFE ASSURANCE Co now owns 22,252 shares of the medical instruments supplier’s stock worth $1,472,000 after purchasing an additional 6,875 shares in the last quarter. Quantbot Technologies LP lifted its stake in shares of LeMaitre Vascular by 1,001.4% during the 1st quarter. Quantbot Technologies LP now owns 7,335 shares of the medical instruments supplier’s stock valued at $487,000 after buying an additional 6,669 shares in the last quarter. Quadrature Capital Ltd increased its holdings in LeMaitre Vascular by 129.4% during the 1st quarter. Quadrature Capital Ltd now owns 22,432 shares of the medical instruments supplier’s stock worth $1,484,000 after acquiring an additional 12,654 shares during the period. Janus Henderson Group PLC increased its holdings in LeMaitre Vascular by 554.7% during the 1st quarter. Janus Henderson Group PLC now owns 55,730 shares of the medical instruments supplier’s stock worth $3,697,000 after acquiring an additional 47,218 shares during the period. Finally, Sequoia Financial Advisors LLC bought a new stake in LeMaitre Vascular during the 2nd quarter worth approximately $1,010,000. Institutional investors own 84.64% of the company’s stock.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.